echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The world's top 10 hot target new drug sales profile: PD-1/PD-L1 market size of more than $23 billion.

    The world's top 10 hot target new drug sales profile: PD-1/PD-L1 market size of more than $23 billion.

    • Last Update: 2020-08-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    A popular target is not a success, the development phase of bright clinical data is important, but ultimately rely on commercial sales after the market performance to speak.
    we are refocusing our attention today on the market performance of hot-and-medium new drugs that have been of great interest in recent years.
    PD-1/PD-L1 PD-L1 and PD-1 are the relationship between the binder and the receptacle, and the combination of the two will provide tumor cells with a "life path" to escape the immune system.
    specifically, PD-L1 is mainly expressed on the surface of tumor cells, PD-1 is mainly expressed on the surface of T cells, when PD-L1 and PD-1 binding, then the T-cell activity is inhibited and lose the original lethal effect, the tumor will be able to grow.
    immunotherapy, which targets PD-1/PD-L1, has also opened a new chapter in tumor clinical treatment.
    since 2014, 10 PD-1/PD-L1 drugs have been approved for marketing worldwide, including four domestic PD-1 monosymlytic drugs listed only in China.
    , which is owned by Theo Heng Pharmaceuticals, also filed a listing application in China on February 18.
    PD-1/PD-L1 circuit is getting more crowded, the market for these drugs is expanding at an alarming rate, with more than $23 billion in just five years.
    Note: Junshi Toshiyi (Trepri mitaab) sales of 775 million yuan (approximately $110 million) in 2019; Ono Pharmaceuticals Opdivo sales in Japan for fiscal 2018 were 90.6 billion yen (approximately $860 million), and fiscal 2019 data has not been disclosed.
    by specific variety, Keytruda has become a big drug with annual sales of more than $10 billion, and its lead is hard to shake.
    O drug growth stalled, temporarily ranked 2nd in the market.
    T drug, I drug is the PD-1/PD-L1 track of the 2nd Group army, catch up with o drug growth momentum is strong.
    domestic PD-1 sales performance has not yet been fully public, only from the performance of 775 million yuan, the Chinese market capacity is very considerable.
    GLP-1R GLP-1R GGL-like peptide 1 (GLP-1) is a natural secretion of the body's gastrointestinal mucosa, which binds to receptors on islet cells and stimulates insulin secretion, which in turn reduces blood sugar. The advantage of
    GLP-1 receptacleant glycosate-lowering drugs is that the rate of hypoglycemia events is significantly lower than insulin, and can reduce food intake and delay stomach emptying, which is beneficial to weight control and protect islet beta cell function.
    Although GLP-1R is not a new target, but with the dual effects of sugar reduction and weight loss and the convenience of once a week, the development of long-acting GLP-1 recepposant agitants has become a hot spot, and from the market performance, is also the best performance of the sugar-lowering drug market (fastest growth) in a segment of the field.
    so far, a total of 8 GLP-1R agonists have been approved worldwide, including four long-acting GLP-1R agonists that can be injected once a week, namely, Abilutide (GSK), dglutade (Lilly), Somalutide (No. Nord), and Lothian (Haussen).
    GLP-1R agonisant-class sugar-lowering drug market size is close to $10 billion.
    Nordisk and Nordisk rely on liraglutide and Somarutide for 51% of the share, while Lilly has a 42% share of Trulicity.
    the two companies dominated the GLP-1R drug market, which also made GSK's Aberystwyth life unexpected, Sanofi decided to abandon the development of new diabetes drugs.
    Lilly Trulicity's 2019 sales of $4,128 million are the best-selling GLP-1R drugs, but Novo Nordiske's Ozempic also quickly reached a high of $1,685 million in its second year on the market, and the oral agent Rybelsus also earned $7 million in a short time to market.
    and somaglutide are the most watched groups in the diabetes drug market in the future.
    BTK Bruton tyrosine kinasse (Bruton's tyrosine kinase, BTK) is an important signal molecule of B-cell receptor pathway, expressed in various stages of B lymphocyte development, participated in regulating the proliferation, differentiation and apoptosis of B cells, plays an important role in the survival and diffusion of malignant B cells, is currently a hot research topic for B-cell tumors and B-cell immune diseases.
    three BTK inhibitors are currently on the market, with a market size of more than $8 billion, but the market share is almost exclusive to Ibtini.
    AbbVie, which owns Ibdini's U.S. market business rights, has now accumulated $13.423 billion in sales from Ibdini after spending $21 billion on the acquisition in 2015 and is expected to recover its original acquisition costs by the end of 2021.
    also acquired the commercial rights to Calquence, a BTK inhibitor, through a large acquisition.
    2019 Calquence's recourse extends from set-cell lymphoma in smaller populations to CLL/SLL in larger populations, and is a first-line therapy.
    Calquance's sales revenue has a relatively good expansion momentum in 2019 and is expected to improve even more in 2020. zebutini,
    , is the world's third-listed BTK inhibitor, due to the SHORT time to obtain FDA approval, the specific results of the Baiji Shenzhou financial report disclosure.
    two new drug listing applications (NDA) for patients with recurrent/refractive encell lymphoma and chronic lymphocytic leukemia or small lymphocytic lymphoma have been prioritized by NMPA in the country and are under review.
    CDK4/6 CDK4/6 is a key factor in regulating cell cycles, triggering the transition of cell cycles from growth (G1 phase) to DNA replication period (phase S), and CDK4/6 inhibitors block cell cycles from G1, thereby inhibiting tumor cell proliferation.
    In all breast cancer patients, hormone receptor-positive (HR-plus) and HER2-negative (HER2-) breast cancer patients account for about 75 percent, and these patients usually use endocrine therapy, but the effectiveness of treatment is limited by drug resistance.
    the appearance of CDK4/6 inhibitors changed the outcome of treatment in patients with HR-/HER2-breast cancer, which can effectively overcome or delay the appearance of endocrine resistance and strive for longer survival time for patients.
    currently approved three CDK4/6 inhibitors worldwide, with a market size of more than $6 billion, of which Pfizer Ibrance has 82.4 percent of the market, with a clear market first-mover advantage.
    Lilly Verzenio and Novartis Kisqali both have significant growth in 2019 and are now on par.
    the world's fastest-growing CDK4/6 inhibitor, in addition to the three drugs mentioned above, is Hengrui's SHR6390, which is currently in Phase III.
    other company projects are in the pre-Phase II phase.
    JAK JAK kinase is a family of non-receptor tyrosine kinase in cells, with four members, JAK-1, JAK-2, JAK-3 and TYK-2.
    JAK kinase mediates signaling of most cytokines in cells, such as leukin (IL), interferon (IFN), and different receptors activate different subsystic JAK kinases to represent different biological functions.
    the potential for JAK inhibitors is therefore very diverse.
    Currently, six JAK inhibitors have been approved worldwide, with a market size of approximately US$5.5 billion, with the largest share being the JAK1/2 inhibitor Rusotini jointly developed by Incyte/Novarhua, which is mainly used to treat blood diseases such as bone marrow fibrosis and true red blood cell growth, with sales of US$2,799 million in 2019.
    Note: Incyte is responsible for the U.S. market of Russotini, Novartis is responsible for Russotini's market outside the U.S. Pfizer's Xeljan (Tofatib) is a JAK2/3 inhibitor, approved for indications focused on autoimmune diseases, including rheumatoid arthritis, ulcerative colitis and psoriasis arthritis, with sales of $2.242 billion in 2019.
    tofatibum is also developed with plaque-like psoriasis, juvenile isoarthritis, and aggressive spinabitis.
    Lilly's Olumiant, a JAK1/2 inhibitor currently approved for rheumatoid arthritis, with sales of $427 million in 2019.
    Baritinib's next major indicationisis is systemic lupus erythematosus, adhesion dermatitis, both areas of disease to choose drugs are not many, there is also a huge market demand.
    JAK drug market added three players in 2019, including AbbVie's JAK1 inhibitor Rinvoq (upadacitinib) for the treatment of rheumatoid arthritis;
    IL-17A IL-17A belongs to the interleukin-17 (Interleukin-17, IL-17) family.
    IL-17 was first discovered by researchers in 1993, and subsequent studies have found that IL-17 plays an important role in host defense, the onset of autoimmune diseases, and tumors, so IL-17 research has become a hot topic in medical and immunology research.
    il-17A play an important role in promoting inflammatory states in the autoimmune responses of diseases such as psoriasis, psoriasis arthritis and severe spina blinthrosis (AS).
    two drugs targeting IL-17A targets are currently on the market, with a market size of $4,917 million.
    Novartis Cosentyx (secukinumab), approved in 2015/1/21, is the world's first listed anti-IL-17A monoantine, currently approved for the treatment of plaque psoriasis, psoriasis arthritis, aggressive spina bifida, sales in 2019 reached $3.551 billion, has become Novartis's current sales of the highest annual product.
    Lilly Taltz (ixekizumab), approved on 3/22/2016, is the world's second-listed anti-IL-17A monoantidrug, similar to the currently approved indications Cosentyx, with sales of $1.366 billion in 2019.
    after Cosentyx and Taltz, the fastest-growing IL-17A projects include bimekizumab (UCB, Phase III), remtolumab (AbbVie, Phase II), vunakizumab (Henri, Phase II), etc.
    PARP PARP is a polyadenosine diphosphate polymerase, an important DNA damage repair protein in cells, mainly repairing single-stranded damage to DNA, while BRCA mainly repairs double-stranded damage in DNA.
    for tumors with BRCA1 or BRCA2 mutations, DNA damage repair in tumor cells will be more dependent on PARP because of the inactivation of the BRCA protein.
    if the activity of PARP is further inhibited by the use of inhibitors, there is a lot of DNA damage when tumor cells divide, which eventually leads to their death.
    four PARP inhibitors are currently on the market, with a market size of about $1.6 billion.
    Lynparza, the FDA's first PARP inhibitor, has expanded its ovarian cancer (including fallopian tube, peritoneal, breast and pancreatic cancer) to the $1 billion bombshell threshold in 2019.
    addition to this, Olapa's application for new adaptive drugs for the treatment of metastatic degenerative prostate cancer has been granted priority review by the FDA and is expected to be approved by 2020Q2.
    GSK/Tesaro's Zejula (Nirapali) is the third listed PARP inhibitor in the world, due to its high bioavailability and longer half-life characteristics, the realization of daily administration, as an ovarian cancer maintenance therapy compared to Lynparza, Rubraca has the advantage of drug-dependent, and therefore also showed good growth momentum.
    , Olapari and Nirapali are all listed in China.
    Hengrui's fluorapyri Pali has filed for listing and is expected to become the world's fifth listed PARP inhibitor.
    the mechanism of action of PARP inhibitors in a unique and complementary way, and is expected to play a greater role in more cancer ousates with other drugs.
    PCSK9 PCSK9 (preprotein-converting enzyme herblycein 9) is a nerve cell apoptosis regulatory conversion enzyme, not only involved in liver regeneration, regulation of nerve cell apoptosis, but also with the liver cell surface of the low density lipoprotein receptor (LDLR) binding, dry recirculation around the LDLR, disturbance reduces the liver from the blood removal LDL-C ability, which leads to high cholesterol.
    studies have shown that PCSK9 levels are significantly associated with cholesterol, ox-LDL, and triglycerides, and are recognized as the most effective lipid-lowering targets after statins.
    Worldwide currently approves two PCSK9 inhibitors, Amgen's Repatha (Iloyu sepsis) and Sanofi/Regeneron's Praluent (Alisiyu sepsis), which have been approved in China.
    reliable clinical data confirmed for the efficacy and cardiovascular benefits of LDL-C, the two drugs were initially highly priced and the market was less receptive, with a market size of only $490 million in 2017.
    an agreement between Amgentand and Sanofi/Regenerative dollars in 2018 to reduce the annual cost of treatment to about $14,000 to between $4,500 and 6,600.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.